KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cardlytics (CDLX) Invested Capital (2016 - 2025)

Cardlytics (CDLX) has disclosed Invested Capital for 10 consecutive years, with $206.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Invested Capital fell 28.59% year-over-year to $206.1 million, compared with a TTM value of $206.1 million through Dec 2025, down 28.59%, and an annual FY2025 reading of $206.1 million, down 28.59% over the prior year.
  • Invested Capital was $206.1 million for Q4 2025 at Cardlytics, up from $41.4 million in the prior quarter.
  • Across five years, Invested Capital topped out at $875.1 million in Q4 2021 and bottomed at $41.4 million in Q3 2025.
  • Average Invested Capital over 5 years is $407.5 million, with a median of $340.4 million recorded in 2023.
  • The sharpest move saw Invested Capital skyrocketed 447.51% in 2021, then tumbled 85.38% in 2025.
  • Year by year, Invested Capital stood at $875.1 million in 2021, then tumbled by 75.82% to $211.6 million in 2022, then skyrocketed by 85.39% to $392.3 million in 2023, then dropped by 26.44% to $288.6 million in 2024, then dropped by 28.59% to $206.1 million in 2025.
  • Business Quant data shows Invested Capital for CDLX at $206.1 million in Q4 2025, $41.4 million in Q3 2025, and $104.7 million in Q2 2025.